Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1616-1621

  Létienne, Robert ^a   Leparq Panissié, Anne ^a   Calmettes, Yannick ^a   Nadal Wollbold, Florence ^a   Perez, Michel ^a   Le Grand, Bruno ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

PAR1 antagonist; Rat; Thrombosis model

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; F 16618; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG STRUCTURE; EXTRACORPOREAL CIRCULATION; HEMODYNAMICS; HUMAN; HUMAN CELL; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; ARTERIOVENOUS SHUNT, SURGICAL; ASPIRIN; BLEEDING TIME; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; MALE; PIPERAZINES; PLATELET AGGREGATION; PYRIDINES; RATS; RECEPTOR, PAR-1; THROMBOSIS; TICLOPIDINE;

EID: 77950068790     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.006     Document Type: Article

References (36)

1. McNicol A., Israels S.J. Platelets and anti-platelet therapy. J Pharmacol Sci 2003, 93:381-396.
2. Levine M.N., Raskob G., Beyth R.J., Kearon C., Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP Conference on Antithrombotic and Thrombolysis Therapy. Chest 2004, 126:287S-310S.
3. Hollenberg M.D., Compton S.J. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002, 54:203-217.
4. Steinhoff M., Buddenkotte J., Shpacovitch V., Rattenholl A., Moormann C., Vergnolle N., et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005, 26:1-43.
5. Vu T.K., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64:1057-1068.
6. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386:502-506.
7. Kahn M.L., Hammes S.R., Botka C., Coughlin S.R. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem 1998, 273:23290-23296.
8. Nystedt S., Emilsson K., Larsson A.K., Strombeck B., Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 1995, 232:84-89.
9. 2+ mobilization. FEBS Lett 1991, 288:123-128.
10. Xu W.F., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P., Ching A., et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998, 95:6642-6646.
11. Kahn M.L., Zheng Y.W., Huang W., Bigornia V., Zeng D., Moff S., et al. A dual thrombin receptor system for platelet activation. Nature 1998, 394:690-694.
12. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999, 103:879-887.
13. Kinlough-Rathbone R.L., Rand M.L., Packham M.A. Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets. Blood 1993, 82:103-106.
14. Létienne R., Leparq-Panissié A., Bocquet A., Calmettes Y., Culié C., Le Grand B. PAR1 antagonist mediated antithrombotic activity in extracorporeal arterio-venous shunt in the rat. Thromb Res 2010, 125:257-261.
15. Connolly T.M., Condra C., Feng D.M., Cook J.J., Stranieri M.T., Reilly C.F., et al. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994, 72:627-633.
16. Colotta F., Sciacca F.L., Sironi M., Luini W., Rabiet M.J., Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994, 144:975-985.
17. Van Gils J.M., Zwaginga J.J., Hordijk P.L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009, 85:195-204.
18. Goldsmith H.L., Turitto V.T. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-report-subcommittee on rheology of the international committee on thrombosis and haemostasis. Thromb Haemost 1986, 55:415-435.
19. Smith L.J., Schaible K.L., Fessler R.G., Rachlin J.R., Brown F.D. Examination of the utility of the rat as an animal model for human anticoagulation. Haemostasis 1987, 17:206-210.
20. Shand R.A., Smith J.R., Wallis R.B. Expression of the platelet procoagulant activity in vivo in thrombus formation in an extracorporeal shunt in the rat. Thromb Res 1984, 36:223-232.
21. Bocquet A., Létienne R., Sablayrolles S., De Vries L., Perez M., Le Grand B. Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction. Eur J Pharmacol 2009, 611:60-63.
22. Perez M., Lamothe M., Maraval C., Mirabel E., Loubat C., Planty B., et al. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem 2009, 52:5826-5836.
23. Freund M., Mantz F., Nicolini P., Gachet C., Mulvihill J., Meyer L., et al. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Thromb Haemostasis 1993, 69:515-521.
24. De Clerck F., Goossens J., Reneman R. Effects of anti-inflammatory, anticoagulant and vasoactive compounds on tail bleeding time, whole blood coagulation time and platelet retention by glass beads in rats. Thromb Res 1976, 8:179-193.
25. Wollny T., Iacoviello L., Buczko W., De Gaetano G., Donati M.B. Prolongation of bleeding time by acute hemolysis in rats: a role for nitric oxide. Am J Physiol 1997, 272:H2875-H2884.
26. Bodary P.F., Eitzman D.T. Animal models of thrombosis. Curr Opin Hematol 2009, 16:342-346.
27. Gill T.J., Smith G.J., Wissler R.W., Kunz H.W. The rat as an experimental animal. Science 1989, 245:269-276.
28. Philp R.B., Francey I., Warren B.A. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. Haemostasis 1978, 7:282-293.
29. Fuster V., Chesebro J.H. Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets (first of three parts). Mayo Clin Proc 1981, 56:102-112.
30. Bird J.E., Giancarli M.R., Allegretto N., Barbera F., Wong P., Schumacher W.A., et al. Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea-pig models of thrombosis and hemostasis. Thromb Res 2008, 123:146-158.
31. Patrono C., Coller B., FitzGerald G.A., Hirsh J., Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:234S-264S.
32. Gurbel P.A., Bliden K.P., DiChiara J., Newcomer J., Weng W., Neerchal N.K., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007, 115:3156-3164.
33. 2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 1993, 69:268-271.
34. Herbert J.M., Savi P., Maffrand J.P. Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. Eur Heart J 1999, 1:A31-40.
35. Strande J.L., Hsu A., Su J., Fu X., Gross G.J., Baker J.E. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol 2007, 102:350-358.
36. Becker R.C., Moliterno D.J., Jennings L.K., Pieper K.S., Pei J., Niederman A., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373:919-928.